Xenetic presents preclinical data on DNase I with CAR T cells in murine model
Research Findings: Xenetic Biosciences presented preclinical data showing that co-administration of deoxyribonuclease I (DNase I) with CAR T cells significantly suppressed lung metastasis in a murine melanoma model, enhancing tumor control and survival compared to CAR T cell therapy alone.
Immune Response Improvement: The combination treatment led to increased infiltration of T and CAR T cells in tumors and reduced markers of T cell exhaustion, indicating that DNase I helps counteract the immunosuppressive environment of tumors.
Trade with 70% Backtested Accuracy
Analyst Views on XBIO
About XBIO
About the author
What’s Driving the Rise of Pharmaceutical Stocks XBIO, UPC, XTLB, and ACXP Today?
Pharmaceutical Stock Movements: Several pharmaceutical stocks, including Xenetic Biosciences, Universe Pharmaceuticals, XTL Biopharmaceuticals, and Acurx Pharmaceuticals, saw significant pre-market gains despite no clear news or announcements explaining the rise.
Speculative Trading Influence: The surge in these stocks may be linked to speculative trading following a massive rally in Galecto shares, which spiked without news and then fell, indicating that retail traders are shifting their focus to other stocks for potential gains.
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Earnings Performance: Xenetic Biosciences reported a quarterly loss of $0.45 per share, better than the expected loss of $0.64, marking a 29.69% earnings surprise; however, revenues of $0.59 million fell short of estimates by 7.81%.
Market Outlook: The company's stock has underperformed with a 30.8% decline this year, and its future performance will depend on management's commentary and revisions to earnings estimates, currently rated as Zacks Rank #3 (Hold).
